Zevra Therapeutics Shares Rise 21.7% on Q4 Beat and GeneDx NPC Testing Pact
Zevra Therapeutics reported Q4 earnings of $0.19 per share on $34.1M revenue, surpassing analyst forecasts by $0.14 and $6M, and held $62.4M cash at end-2025. The firm’s FY25 revenue jumped 350% to $106.5M on Miplyffa uptake and partnered with GeneDx to expand ExomeDx NPC testing.
1. Q4 Results Beat Expectations
Zevra reported Q4 earnings of $0.19 per share, topping estimates by $0.14, and generated $34.1 million in revenue, exceeding forecasts by $6 million. The quarter ended with $62.4 million in cash and equivalents, strengthening the balance sheet ahead of 2026 initiatives.
2. FY25 Commercial Momentum
Full-year 2025 revenue surged 350% to $106.5 million, driven by rapid adoption of Miplyffa for Niemann-Pick Type C patients. Expanded payer coverage and diagnostic support underpinned record sales growth in the ultra-rare disease market.
3. GeneDx Partnership Expands NPC Testing
The partnership with GeneDx will extend access to its ExomeDx exome sequencing test for suspected NPC, aiming to accelerate precise diagnosis and early patient identification. This collaboration leverages the GeneDx Infinity rare-disease genomic dataset to inform clinical and biopharma efforts.
4. Strategic Outlook and Headquarters Relocation
Zevra relocated its global headquarters to Boston to tap into specialized rare-disease talent and has outlined multiple near-term growth opportunities for 2026. Management expects continued commercial and diagnostic initiatives to drive shareholder value.